Home › Funds › Trails Edge Capital Partners, LP › VRDN

Trails Edge Capital Partners, LP position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Trails Edge Capital Partners, LP reported holding 2,495,660 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$34.3M, representing 4.92% of its reported portfolio and ranking #4 among its reported holdings. Trails Edge Capital Partners, LP first reported this position in Q3 2026.

Latest position (Q3 2026)2.50M sh
Reported value held$34.27M
Portfolio Weight4.92%
First reportedQ3 2026
Last changeNew
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Trails Edge Capital Partners, LP's VRDN position evolved

Trails Edge Capital Partners, LP first disclosed a stake in VRDN in Q3 2026 at 2,495,660 shares (US$34.3M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 2.50M $34.27M New

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Trails Edge Capital Partners, LP held VRDN?

Trails Edge Capital Partners, LP has disclosed VRDN holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Trails Edge Capital Partners, LP's current position in VRDN?

As of Q3 2026, Trails Edge Capital Partners, LP holds 2.50M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $34.27M, representing 4.92% of its reported portfolio and ranking #4.

Has Trails Edge Capital Partners, LP been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Trails Edge Capital Partners, LP newly opened its position in VRDN.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.